Using our patented Accuracy and Content Enhanced (ACE) Technology, the ACE Research Exome outperforms conventional exome assays by augmenting coverage across intronic and difficult-to-sequence regions (including regions of high-GC content) of >8,000 biomedically-important genes, including >1,400 cancer-related genes. The application of this technology ensures the delivery of more complete and uniform coverage of targeted gene regions; resulting in the more accurate and reliable capture of both germline and somatic single-nucleotide variants (SNVs), insertions/deletions (indels), and copy number alterations (CNAs) that might otherwise be missed.
Personalis’ ability to extract the maximum amount of usable data from each sample is also empowered by our unique sample-sparing protocols for all sample types.
|Genes augmented (with ACE Technology)||>8,000 biomedically-relevant genes, including >1,400 cancer-related genes|
|Sequencing information||Configuration: ~120X|
Read length: 2x150bp
Instrumentation: Illumina NovaSeq
|Cancer analysis configuration||Paired tumor/normal or tumor only|